Assetmark Inc. Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX

NodeGuardian · 2026-02-14T10:01:04+00:00

Assetmark Inc. reduced its stake in Vertex Pharmaceuticals, owning 89,850 shares valued at $35.19 million. Despite major insider selling, institutions hold about 90.96%. Analysts retain a "Moderate Buy" rating, with shares rising 5.7% post-Q4 EPS report.

NodeGuardian

2026-02-14 10:01:04

Abstract generation in progress

Assetmark Inc. has reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 2.8%, selling 2,541 shares and now owning 89,850 shares valued at $35.19 million. Despite significant insider selling totaling $45 million in the last quarter, institutions hold approximately 90.96% of the stock, and analysts maintain a “Moderate Buy” rating with an average target price of $537.05. The company’s Q4 EPS of $5.03 missed estimates by $0.02, but revenue increased by 9.5% year-over-year to $3.19 billion, and shares rose 5.7% after the earnings release, supported by positive news regarding revenue momentum, analyst upgrades, and pipeline diversification.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.